SCHEMBL1663409

SCHEMBL1663409

COc1ccc(-n2c(C(C)C)nc3cc(O)ccc3c2=O)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.69
ESR1 P03372 2/20 0.58
ESR2 Q92731 1/20 0.58
PDE10A Q9Y233 3/20 0.49
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
MAPT P10636 2/20 0.48
KDM4E B2RXH2 1/20 0.48
TSHR P16473 1/20 0.48
CASP1 P29466 1/20 0.48
AHR P35869 1/20 0.48
CASP7 P55210 1/20 0.48
HSD17B10 Q99714 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
ALDH1A1 P00352 3/20 0.47
KCNH2 Q12809 1/20 0.47
HRH3 Q9Y5N1 1/20 0.47
TRPV4 Q9HBA0 2/20 0.47
LMNA P02545 2/20 0.46
RAB9A P51151 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663899 0.88 TRPV1 (0.60) TRPV1ESR1ESR2MEN1KMT2A
SCHEMBL1664439 0.86 TRPV1 (0.74) TRPV1ESR1ESR2PDE10AHSD17B10
SCHEMBL1664011 0.85 TRPV1 (0.72) TRPV1ESR1ESR2MEN1KMT2A
SCHEMBL10446158 0.85 TRPV1 (0.72) TRPV1ESR1ESR2MAPTKDM4E
SCHEMBL1663398 0.85 TRPV1 (0.72) TRPV1ESR1ESR2PDE10AMEN1
SCHEMBL1663637 0.85 TRPV1 (0.65) TRPV1ESR1ESR2MEN1KMT2A
SCHEMBL1665294 0.84 TRPV1 (0.70) TRPV1ESR1ESR2PDE10AMEN1
SCHEMBL1663333 0.83 TRPV1 (0.69) TRPV1ESR1ESR2MAPTALDH1A1
SCHEMBL1066896 0.82 TRPV1 (1.00) TRPV1ESR1ESR2PDE10AKMT2A
SCHEMBL14752483 0.82 TRPV1 (0.79) TRPV1ESR1ESR2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2305652-A2 Trisubstituted quinazolinone derivatives as vanilloid antagonists Novartis AG (CH) 2011-04-06 EP disclosed
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists NOVARTIS AG 2009-03-26 US disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090082365-A1 Trisubstituted Quinazolinone Derivatives as Vanilloid Antagonists TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 1321/4885ESR2 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.